首页> 外文OA文献 >Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial

【2h】

Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial

机译：具有新诊断，晚期卵巢癌（OC）和使用维护（MT）Olaparib（OLA）治疗的新诊断，晚期卵巢癌（OC）和BRCA突变（BRCAM）的患者（PTS）的时间（PFS2）和第二次后续治疗（TSST）。审判

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
A. Oaknin; K. Moore; N. Colombo; G. Scambia; B.-G. Kim; M. Friedlander; A. Lisyanskaya; A. Floquet; A. Leary; G.S. Sonke; C. Gourley; S. Banerjee; A.M. Oza; A. González-Martín; C. Aghajanian; W. Bradley; E.S. Lowe; R. Bloomfield; P. DiSilvestro;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial (Aug, 10.1200/JCO.20.00799, 2020) [J] . DiSilvestro Journal of Clinical Oncology . 2021,第12期

机译：奥拉帕里韦对新诊断的晚期卵巢癌患者的疗效，SOLO1试验的亚组分析结果（8.1200 / JCO.20.00799,2020）
2. Newly diagnosed advanced Ovarian Cancer with BRCA-Mutations Prolonged progression-free Survival with Olaparib film-coated Tablets [J] . Ruedesheim Sabine M. Oncology research and treatment. . 2019,第9期

机译：新诊断患有BRCA-突变的晚期卵巢癌，与奥拉帕里布涂层片剂无进展生存
3. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial [J] . Friedlander Michael, Gebski Val, Gibbs Emma, The lancet oncology . 2018,第8期

机译：在铂敏感，复发卵巢癌和BRCA1 / 2突变患者中，在化疗后，与奥拉帕里韦维持的健康相关的生活质量和患者为中心的结果（Solo2 / engot OV-21）：安慰剂控制，第3期随机试验
4. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial [O] . Richard T. Penson, Ricardo Villalobos Valencia, David Cibula, -1

机译：铂敏感性复发性卵巢癌和生殖细胞BRCA1 / 2突变（SOLO3）患者的Olaparib与非铂化疗：一项随机III期试验
5. 234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 [O] . M.L. Friedlander, K. Moore, N. Colombo, 2020

机译：234O维护奥帕里布患者（PTS）具有新诊断，晚期卵巢癌（OC）和BRCA突变（BRCAM）：5年（Y）随访（F / U）来自Solo1

Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial

著录项

相似文献

相关主题

期刊订阅